デフォルト表紙
市場調査レポート
商品コード
1008154

変形性関節症治療薬の世界市場(2020年~2026年)

Global Osteoarthritis Therapeutics Market 2020-2026

出版日: | 発行: Orion Market Research Pvt Ltd | ページ情報: 英文 | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.84円
変形性関節症治療薬の世界市場(2020年~2026年)
出版日: 2021年05月06日
発行: Orion Market Research Pvt Ltd
ページ情報: 英文
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

変形性関節症治療薬の世界市場:解剖学的構造別(膝、足首、股関節、手、脊椎)、薬剤タイプ別(NSAID、関節内補充療法剤、コルチコステロイド、鎮痛薬)、地域別の、市場規模予測、シェアおよび動向分析レポート(2020年~2026年)

世界の変形性関節症治療薬市場は、予測期間中に8.2%の大幅な成長を目撃すると推定されています。高齢者人口の増加とスポーツ傷害の数の増加は、市場の成長を加速するいくつかの重要な要因です。国連(UN)によると、2050年までに、世界の6人に1人が65歳以上(16%)になり、2019年の11人に1人(9%)から増加します。2019年から2050年には、80歳以上の人が、1億4,300万人から4億2,600万人へと、3倍になると予想されています。65歳以上の人では、変形性関節症は、生物学的老化プロセスに直接寄与する可能性があるため、障害の主な原因の1つです。これにより、関節の損傷や痛みを伴う炎症の予防をサポートする変形性関節症の治療に対する需要が高まっています。また、これは関節のスムーズな動きを促進することができます。

地理的に、アジア太平洋地域は、肥満人口の増加と地域の老人人口ベースの増加と相まった関節炎の発生率の増加により、予測期間中に潜在的な成長を目撃すると推定されています。中国はかなりの肥満人口を抱える国の一つです。人が10ポンド太りすぎの場合、さらに15ポンド~50ポンドの圧力が膝にかかります。これにより、変形性関節症を発症するリスクが高まり、患者がすでに変形性関節症を患っている場合は、変形性関節症を悪化させる可能性があります。過剰な脂肪は関節に有害な負荷をかけ、軟骨に急速に影響を与える可能性があります。したがって、肥満は変形性関節症の主な原因の1つと見なされており、この地域での変形性関節症治療の採用を後押ししています。

市場の主要なプレーヤーには、Pfizer Inc., Bayer AG, Zimmer Biomet Holdings, Inc., Sanofi S.A., GlaxoSmithKline plc.などがあります。製品の発売は、市場でのシェアを増やすために市場のプレーヤーによって採用される潜在的な戦略と見なされます。たとえば、2019年1月、OrthogenRx, Inc.は、理学療法や運動、または単純な鎮痛剤から十分な緩和を得られなかった変形性関節症の膝の痛みの患者を治療するためにTriVisc(ヒアルロン酸ナトリウム)の導入を宣言しました。TriViscは、高度に精製されたヒアルロン酸(ヒアルロン酸ナトリウム:HA)溶液であり、膝関節の液体の粘性特性を補います。

当レポートでは変形性関節症治療薬の世界市場を調査し、市場の概要、市場の成長要因および阻害要因の分析、市場機会、解剖学的構造・薬剤タイプ・地域別の市場規模の推移と予測、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 レポートの概要

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
  • ルールと規則

第3章 競合情勢

  • 重要な戦略分析
  • 主要企業分析
    • Pfizer, Inc.
    • Bayer AG
    • Zimmer Biomet Holdings, Inc.
    • Sanofi S.A.
    • GlaxoSmithKline plc

第4章 市場の決定要因

  • 動機
  • 抑制要因
  • 市場機会

第5章 市場細分化

  • 解剖学的構造別
    • 足首
    • 脊椎
  • 薬剤タイプ別
    • 非ステロイド性抗炎症薬(NSAID)
    • 関節内補充療法剤
    • コルチコステロイド
    • 鎮痛薬

第6章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • その他アジア太平洋地域
  • その他の地域

第7章 企業プロファイル

  • Abbott Laboratories
  • Anika Therapeutics, Inc.
  • Assertio Therapeutics, Inc.
  • Bioventus LLC
  • Eli Lilly and Co.
  • Ferring Pharmaceuticals
  • Fidia Farmaceutici S.p.A.
  • Flexion Therapeutics
  • Hanmi Pharmaceutical Co., Ltd.
  • Horizon Therapeutics plc
  • Iroko Pharmaceuticals, Inc.
  • Johnson & Johnson Service, Inc.
  • Kitov Pharmaceuticals, Ltd.
  • Laboratorio Reig Jofre
  • Novartis International AG
  • OrthogenRx, Inc
  • Virchow Biotech, Pvt. Ltd.
図表

LIST OF TABLES

  • 1. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY ANATOMY, 2019-2026 ($ MILLION)
  • 2. GLOBAL KNEE OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL ANKLE OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL HIP OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 5. GLOBAL HAND OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 6. GLOBAL SPINE OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 7. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2019-2026 ($ MILLION)
  • 8. GLOBAL NSAIDs FOR OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 9. GLOBAL VISCOSUPPLEMENTATION FOR OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 10. GLOBAL CORTICOSTEROIDS FOR OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 11. GLOBAL ANALGESICS FOR OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 12. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 13. NORTH AMERICAN OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 14. NORTH AMERICAN OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY ANATOMY, 2019-2026 ($ MILLION)
  • 15. NORTH AMERICAN OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2019-2026 ($ MILLION)
  • 16. EUROPEAN OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 17. EUROPEAN OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY ANATOMY, 2019-2026 ($ MILLION)
  • 18. EUROPEAN OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2019-2026 ($ MILLION)
  • 19. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 20. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY ANATOMY, 2019-2026 ($ MILLION)
  • 21. ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2019-2026 ($ MILLION)
  • 22. REST OF THE WORLD OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY ANATOMY, 2019-2026 ($ MILLION)
  • 23. REST OF THE WORLD OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SHARE BY ANATOMY, 2019 VS 2026 (%)
  • 2. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2019-2026 ($ MILLION)
  • 3. GLOBAL OSTEOARTHRITIS THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 4. US OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 5. CANADA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. UK OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. FRANCE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. GERMANY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. ITALY OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. SPAIN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. ROE OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. INDIA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. CHINA OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. JAPAN OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 16. REST OF THE WORLD OSTEOARTHRITIS THERAPEUTICS MARKET SIZE, 2019-2026 ($ MILLION)
目次
Product Code: OMR2023447

Global Osteoarthritis Therapeutics Market Size, Share & Trends Analysis Report, By Anatomy (Knee, Ankle, Hip, Hand, and Spine), By Drug Type (NSAIDs, Viscosupplementation Agents, Corticosteroids, and Analgesics) and Forecast, 2020-2026

The global osteoarthritis therapeutics market is estimated to witness significant growth of 8.2% during the forecast period. The rising geriatric population and rising number of sports injuries are some key factors accelerating market growth. As per the United Nations (UN), by 2050, 1 in 6 people globally will be more than the age 65 (16%), increased from 1 in 11 in 2019 (9%). In 2019, the persons aged 80 years, or more are anticipated to triple, from 143 million to 426 million in 2050. In people aged over 65 years, osteoarthritis is one of the key causes of disability, as it may contribute directly to the biological aging process. This, in turn, is driving the demand for osteoarthritis treatment to support the prevention of joint damage and painful inflammation. It can also facilitate the smoother movement of joints.

Geographically, Asia-Pacific is estimated to witness potential growth during the forecast period owing to the rising incidences of arthritis coupled with the rising obese population and increasing geriatric population base in the region. China is among the countries with a considerable obese population. An extra 15 to 50 pounds of pressure puts on the knees when the person is being 10 pounds overweight. This, in turn, increased the risk of developing osteoarthritis or may worsen the disease if the patient already has it. Excess fat can create a harmful load on joints and rapidly affect the cartilage. Therefore, obesity is regarded as one of the major causes of osteoarthritis, which in turn, is supporting to boost the adoption of osteoarthritis treatment in the region.

Some key players in the market include Pfizer Inc., Bayer AG, Zimmer Biomet Holdings, Inc., Sanofi S.A., and GlaxoSmithKline plc. Product launches are regarded as a potential strategy adopted by the market players to increase their share in the market. For instance, in January 2019, OrthogenRx, Inc. declared the introduction of TriVisc (sodium hyaluronate) to treat patients with osteoarthritic knee pain who have failed to get sufficient relief from physical therapy or exercise or simple painkillers. TriVisc is a highly purified hyaluronic acid (sodium hyaluronate; HA) solution and supports supplement the viscous properties of the fluid in the knee joint.

Research Methodology

The market study of the global osteoarthritis therapeutics market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.

Secondary Sources Include

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Osteoarthritis Therapeutics Market Research and Analysis by Anatomy

2. Global Osteoarthritis Therapeutics Market Research and Analysis by Drug Type

The Report Covers

  • Comprehensive research methodology of the global osteoarthritis therapeutics market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global osteoarthritis therapeutics market.
  • Insights about market determinants which are stimulating the global osteoarthritis therapeutics market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules and Regulations

3. Competitive Landscape

  • 3.1. Key Strategy Analysis
  • 3.2. Key Company Analysis
    • 3.2.1. Pfizer, Inc.
      • 3.2.1.1. Overview
      • 3.2.1.2. Financial Analysis
      • 3.2.1.3. SWOT Analysis
      • 3.2.1.4. Recent Developments
    • 3.2.2. Bayer AG
      • 3.2.2.1. Overview
      • 3.2.2.2. Financial Analysis
      • 3.2.2.3. SWOT Analysis
      • 3.2.2.4. Recent Developments
    • 3.2.3. Zimmer Biomet Holdings, Inc.
      • 3.2.3.1. Overview
      • 3.2.3.2. Financial Analysis
      • 3.2.3.3. SWOT Analysis
      • 3.2.3.4. Recent Developments
    • 3.2.4. Sanofi S.A.
      • 3.2.4.1. Overview
      • 3.2.4.2. Financial Analysis
      • 3.2.4.3. SWOT Analysis
      • 3.2.4.4. Recent Developments
    • 3.2.5. GlaxoSmithKline plc
      • 3.2.5.1. Overview
      • 3.2.5.2. Financial Analysis
      • 3.2.5.3. SWOT Analysis
      • 3.2.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Osteoarthritis Therapeutics Market by Anatomy
    • 5.1.1. Knee
    • 5.1.2. Ankle
    • 5.1.3. Hip
    • 5.1.4. Hand
    • 5.1.5. Spine
  • 5.2. Global Osteoarthritis Therapeutics Market by Drug Type
    • 5.2.1. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 5.2.2. Viscosupplementation Agents
    • 5.2.3. Corticosteroids
    • 5.2.4. Analgesics

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. Anika Therapeutics, Inc.
  • 7.3. Assertio Therapeutics, Inc.
  • 7.4. Bioventus LLC
  • 7.5. Eli Lilly and Co.
  • 7.6. Ferring Pharmaceuticals
  • 7.7. Fidia Farmaceutici S.p.A.
  • 7.8. Flexion Therapeutics
  • 7.9. Hanmi Pharmaceutical Co., Ltd.
  • 7.10. Horizon Therapeutics plc
  • 7.11. Iroko Pharmaceuticals, Inc.
  • 7.12. Johnson & Johnson Service, Inc.
  • 7.13. Kitov Pharmaceuticals, Ltd.
  • 7.14. Laboratorio Reig Jofre
  • 7.15. Novartis International AG
  • 7.16. OrthogenRx, Inc
  • 7.17. Virchow Biotech, Pvt. Ltd.